Histopathologische Befundung von Keimzelltumoren – worauf ist zu achten?

Alexander Fichtner; Daniel Nettersheim; Felix Bremmer

doi:10.1055/a-2363-4744

Aktuelle Urologie, Inhaltsverzeichnis

Aktuelle Urol 2024; 55(06): 528-536
DOI: 10.1055/a-2363-4744

Übersicht

Histopathologische Befundung von Keimzelltumoren – worauf ist zu achten?

Histopathological analysis of germ cell tumours: aspects to consider

Alexander Fichtner

¹Institute of Pathology, University Medical Center Göttingen, Göttingen, Germany (Ringgold ID: RIN27177)

,

Daniel Nettersheim

²Klinik für Urologie, Urologisches Forschungslabor, Translationale Uro-Onkologie, Medizinische Fakultät und Universitätskrankenhaus Düsseldorf, Heinrich Heine University Düsseldorf, Düsseldorf, Germany

³Lighthouse Projekt: Keimzelltumoren, Zentrum für integrierte Onkologie Aachen, Bonn und Köln-Düsseldorf (CIO ABCD), Düsseldorf, Germany

,

Felix Bremmer

¹Institute of Pathology, University Medical Center Göttingen, Göttingen, Germany (Ringgold ID: RIN27177)

› Institutsangaben

Abstract

Zusammenfassung

Die Keimzelltumoren machen den Großteil der Hodentumoren aus und bilden eine heterogene Gruppe an Tumoren, die sich biologisch unterschiedlich verhalten. Aufgrund des Auftretens in unterschiedlichen Altersgruppen, ihrer morphologischen Charakteristika und der molekularen Veränderungen werden sie in 3 verschiedene Gruppen (Typ I–III) unterteilt. Die genaue histopathologische Analyse eines Orchiektomieresektats, die Zuordnung in die genannten 3 Gruppen und die genaue Benennung aller Subtypen mit prozentualer Verteilung ist für die Therapie und Prognose eines Patienten mit Keimzelltumor sehr wichtig. In diesem Artikel wird die Vorgehensweise bei der Aufarbeitung eines Orchiektomieresektats und die histopathologische Analyse des Hodentumorgewebes geschildert und dargestellt, in welchen Situationen Hilfsmittel wie immunhistochemische oder molekularpathologische Untersuchungen notwendig sind. Ferner wird die aktuelle Einteilung der Keimzelltumoren des Hodens anhand der gültigen WHO-Klassifikation geschildert und diskutiert.

Abstract

Germ cell tumours (GCT) are the most common testicular tumours and form a heterogenous group of tumours with different biological behaviour. Based on differences regarding patient age at first manifestation, morphological characteristics and molecular changes, they are divided into three different groups of GCTs (type I–III). For treatment and prognosis, an exact histopathological analysis of an orchiectomy resection specimen is very important, including the specification of all different histological subtypes with their proportional distribution. This article describes the approach of the preparation of a resection specimen and the histopathological analysis of a testicular tumour. In addition, it describes cases in which additional tools like immunohistochemical and molecular analyses are necessary. Furthermore, the current WHO classification of testicular GCT is discussed.

Schlüsselwörter

Seminom - Hoden - Keimzelltumor - Nicht-Seminom

Keywords

testicle - germ cell tumour - seminoma - non-seminomatous tumour

Volltext

Referenzen

Literatur
1 WHO Classification of Tumours Editorial Board. Urinary and male genital tumours [Internet]. Lyon (France): International Agency for Research on Cancer; 2022 [cited 2023 09 23]. (WHO classification of tumours series, 5th ed.; vol. 8). Zugriff am 23. September 2023 unter: https://tumourclassification.iarc.who.int/chaptercontent/36/333
2 Ulbright TM, Young RH. Metastatic carcinoma to the testis: a clinicopathologic analysis of 26 nonincidental cases with emphasis on deceptive features. Am J Surg Pathol 2008; 32: 1683-1693
3 Sung H, Ferlay J, Siegel RL. et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin 2021; 71: 209-249
4 Park JS, Kim J, Elghiaty A. et al. Recent global trends in testicular cancer incidence and mortality. Medicine (Baltimore) 2018; 97: e12390
5 Oosterhuis JW, Looijenga LHJ. Human germ cell tumours from a developmental perspective. Nat Rev Cancer 2019; 19: 522-537
6 Oosterhuis JW, Looijenga LHJ. Testicular germ-cell tumours in a broader perspective. Nat Rev Cancer 2005; 5: 210-222
7 Zhou G, Sun F, Yu X. et al. Clinical characteristics and long-term management of prepubertal testicular teratomas: a retrospective, multicenter study. Eur J Pediatr 2023; 182: 1823-1828
8 Pow-Sang J, Sánchez J, Benavente V. et al. Testicular yolk sac carcinoma in infants: natural history in 56 consecutive patients. Prog Clin Biol Res 1985; 203: 623-637
9 Honecker F, Aparicio J, Berney D. et al. ESMO Consensus Conference on testicular germ cell cancer: diagnosis, treatment and follow-up. Ann Oncol 2018; 29: 1658-1686
10 Berney DM, Looijenga LHJ, Idrees M. et al. Germ cell neoplasia in situ (GCNIS): evolution of the current nomenclature for testicular pre-invasive germ cell malignancy. Histopathology 2016; 69: 7-10
11 Fichtner A, Richter A, Filmar S. et al. The detection of isochromosome i(12p) in malignant germ cell tumours and tumours with somatic malignant transformation by the use of quantitative real-time polymerase chain reaction. Histopathology 2021; 78: 593-606
12 Bremmer F, Pongratanakul P, Skowron M. et al. Characterizing the mutational burden, DNA methylation landscape, and proteome of germ cell tumor-related somatic-type malignancies to identify the tissue-of-origin, mechanisms of therapy resistance, and druggable targets. Br J Cancer 2023; 129: 1580-1589
13 Pongratanakul P, Bremmer F, Pauls S. et al. Assessing the risk to develop a growing teratoma syndrome based on molecular and epigenetic subtyping as well as novel secreted biomarkers. Cancer Lett 2024; 585: 216673
14 Talerman A. Spermatocytic seminoma: clinicopathological study of 22 cases. Cancer 1980; 45: 2169-2176
15 Carrière P, Baade P, Fritschi L. Population based incidence and age distribution of spermatocytic seminoma. J Urol 2007; 178: 125-128
16 Hu R, Ulbright TM, Young RH. Spermatocytic Seminoma: A Report of 85 Cases Emphasizing Its Morphologic Spectrum Including Some Aspects Not Widely Known. Am J Surg Pathol 2019; 43: 1-11
17 Gupta S, Farooq A, Rowsey RA. et al. Cytogenetics of spermatocytic tumors with a discussion of gain of chromosome 12p in anaplastic variants. Hum Pathol 2022; 124: 85-95
18 International Germ Cell Consensus Classification: a prognostic factor-based staging system for metastatic germ cell cancers. International Germ Cell Cancer Collaborative Group. JCO 1997; 15: 594-603
19 Talerman A, Haije WG, Baggerman L. Serum alphafetoprotein (AFP) in patients with germ cell tumors of the gonads and extragonadal sites: correlation between endodermal sinus (yolk sac) tumor and raised serum AFP. Cancer 1980; 46: 380-385
20 Alvarado-Cabrero I, Hernández-Toriz N, Paner GP. Clinicopathologic analysis of choriocarcinoma as a pure or predominant component of germ cell tumor of the testis. Am J Surg Pathol 2014; 38: 111-118
21 Butcher DN, Gregory WM, Gunter PA. et al. The biological and clinical significance of HCG-containing cells in seminoma. Br J Cancer 1985; 51: 473-478
22 Verrill C, Perry-Keene J, Srigley JR. et al. Intraoperative Consultation and Macroscopic Handling: The International Society of Urological Pathology (ISUP) Testicular Cancer Consultation Conference Recommendations. Am J Surg Pathol 2018; 42: e33-e43
23 S3-Leitlinie Keimzelltumoren des Hodens AWMF-Registernummer: 043/049OL. https://www.leitlinienprogramm-onkologie.de/leitlinien/hodentumoren 2019
24 Testicular dysgenesis syndrome: an increasingly common developmental disorder with environmental aspects – PubMed. Zugriff am 22. Januar 2024 unter: https://pubmed.ncbi.nlm.nih.gov/11331648/
25 Balzer BL, Ulbright TM. Spontaneous Regression of Testicular Germ Cell Tumors: An Analysis of 42 Cases. The American Journal of Surgical Pathology 2006; 30: 858-865
26 Rabade K, Panjwani PK, Menon S. et al. Spermatocytic tumor of testis: A case series of 26 cases elucidating unusual patterns with diagnostic and treatment dilemmas. J Cancer Res Ther 2022; 18: S449-S454
27 Müller MR, Skowron MA, Albers P. et al. Molecular and epigenetic pathogenesis of germ cell tumors. Asian J Urol 2021; 8: 144-154
28 Cao D, Li J, Guo CC. et al. SALL4 is a novel diagnostic marker for testicular germ cell tumors. Am J Surg Pathol 2009; 33: 1065-1077
29 Kommoss F, Oliva E, Bittinger F. et al. Inhibin-alpha CD99, HEA125, PLAP, and chromogranin immunoreactivity in testicular neoplasms and the androgen insensitivity syndrome. Hum Pathol 2000; 31: 1055-1061
30 Jong J de, Stoop H, Gillis AJM. et al. Differential expression of SOX17 and SOX2 in germ cells and stem cells has biological and clinical implications. J Pathol 2008; 215: 21-30
31 Lau SK, Weiss LM, Chu PG. D2–40 immunohistochemistry in the differential diagnosis of seminoma and embryonal carcinoma: a comparative immunohistochemical study with KIT (CD117) and CD30. Mod Pathol 2007; 20: 320-325
32 Osman H, Cheng L, Ulbright TM. et al. The utility of CDX2, GATA3, and DOG1 in the diagnosis of testicular neoplasms: an immunohistochemical study of 109 cases. Hum Pathol 2016; 48: 18-24
33 Motoyama T, Watanabe H, Yamamoto T. et al. Production of beta-human chorionic gonadotropin by germ cell tumors in vivo and in vitro. Acta Pathol Jpn 1988; 38: 577-590
34 Looijenga LHJ, Hersmus R, Gillis AJM. et al. Genomic and expression profiling of human spermatocytic seminomas: primary spermatocyte as tumorigenic precursor and DMRT1 as candidate chromosome 9 gene. Cancer Res 2006; 66: 290-302
35 Colecchia M, Necchi A, Paolini B. et al. Teratoma with somatic-type malignant components in germ cell tumors of the testis: a clinicopathologic analysis of 40 cases with outcome correlation. Int J Surg Pathol 2011; 19: 321-327
36 Fichtner A, Richter A, Filmar S. et al. Primary mediastinal germ cell tumours: an immunohistochemical and molecular diagnostic approach. Histopathology 2022; 80: 381-396
37 Albers P, Ulbright TM, Albers J. et al. Tumor proliferative activity is predictive of pathological stage in clinical stage A nonseminomatous testicular germ cell tumors. J Urol 1996; 155: 579-586